Page last updated: 2024-12-06

tranylcypromine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tranylcypromine is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) that has been used to treat depression and other mood disorders. It was first synthesized in the 1950s and introduced as a medication in the 1960s. Its mechanism of action involves inhibiting the enzyme monoamine oxidase, which breaks down neurotransmitters like serotonin, norepinephrine, and dopamine in the brain. This inhibition leads to increased levels of these neurotransmitters, which can improve mood and alleviate symptoms of depression. Tranylcypromine is known for its rapid onset of action and its effectiveness in treating severe cases of depression that have not responded to other treatments. However, it can also interact with a wide range of medications and foods, and it can cause significant side effects, including potentially life-threatening interactions. Due to these risks, its use is generally reserved for patients who have not responded to other treatments and who are closely monitored by a healthcare professional. Research on tranylcypromine has focused on understanding its effectiveness and safety, as well as exploring its potential uses in other conditions, such as anxiety disorders and Parkinson's disease. Its unique mechanism of action and its potential to provide benefits in difficult-to-treat conditions continue to make it an important subject of ongoing research.'

Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

(1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID19493
CHEMBL ID1179
CHEBI ID131510
CHEBI ID94631
CHEBI ID9652
SCHEMBL ID34339
MeSH IDM0021846

Synonyms (125)

Synonym
AC-15970
BRD-K47029922-003-03-4
PRESTWICK2_000173
(1r,2s)-2-phenylcyclopropanamine
hsdb 3404
parnitene
skf trans-385
(+)-(r)-tranylcypromine
trans-(-)-2-phenylcyclopropanamine
tranylcyprominum [inn-latin]
d-tranylcypromine
l-tranylcypromine
2-phenyl-1-aminocyclopropane, trans-
tranilcipromina [inn-spanish]
einecs 205-841-9
tranylcypromine [inn:ban]
nsc 80664
cyclopropanamine, 2-phenyl-, trans-(+-)-
cyclopropanamine, 2-phenyl-, (1r-trans)-
ccris 3344
cyclopropylamine, 2-phenyl-, (1s-trans)-
brn 2802413
brn 3195803
cyclopropylamine, 2-phenyl-, trans-(+-)-
cyclopropylamine, 2-phenyl-, trans-(-)-
cyclopropylamine, 2-phenyl-, trans-(.+/-.)-
cyclopropanamine, 2-phenyl-, trans-(.+/-.)-
NCGC00015848-01
lopac-p-8511
PDSP2_001080
PDSP2_001079
CBCHROMO1_000132
transamine
skf 385
nsc80664
nsc-80664
parnate
tranylcypromine
155-09-9
trans-2-phenylcyclopropylamine
racemic tranylcypromine
trans-dl-2-phenylcyclopropylamine
(1r*,2s*)-2-phenylcyclopropan-1-amine
(+/-)-trans-2-phenylcyclopropylamine
SPBIO_001986
PRESTWICK1_000173
PRESTWICK0_000173
trans 2 phenylcyclopropylamine
jatrosom
(tranylcypromine)2-phenyl-cyclopropylamine
rel-tranylcypromine
cid_2723716
(1r,2s)-(-)-2-phenylcyclopropylamine
bdbm50240772
2-phenyl-cyclopropylamine
trans-2-phenylcyclopropanamine
gjz ,
95-62-5
CHEMBL1179 ,
(1r,2s)-2-phenyl-1-cyclopropanamine
trans-2-phenylcyclopropan-1-amine
(1r,2s)-trans-tranylcypromine
(1r,2s)-tranylcypromine
CHEBI:131510
3721-26-4
(1r,2s)-2-phenylcyclopropan-1-amine
AKOS006282586
tranilcipromina
3e3v44j4z9 ,
cyclopropanamine, 2-phenyl-, (1r,2s)-rel-
tranylcyprominum
3-12-00-02797 (beilstein handbook reference)
unii-3e3v44j4z9
tranylcypromine [inn]
tranylcypromine [hsdb]
cyclopropanamine, 2-phenyl-, (1s,2r)-
tranylcypromine [mi]
tranylcypromine [vandf]
tranylcypromine [who-dd]
SCHEMBL34339
[(trans)-2-phenylcyclopropyl]amine
trans amine
trans-amine
trans-2-phenyl cyclopropylamine
trans-2-phenyl-cyclopropylamine
[trans-2-phenylcyclopropyl]amine
(1r-trans)-2-phenyl-cyclopropanamine
(trans)-2-phenylcyclopropanamine
(1r,2s)-2-phenyl-cyclopropylamine
skf-trans-385
(.+/-.)-trans-2-phenylcyclopropamine
parnate (salt/mix)
(.+/-.)-tranylcypromine
(.+/-.)-trans-2-phenylcyclopropylamine
(1r,2s)-rel-2-phenylcyclopropan-1-amine
DTXSID2023694 ,
(1r,2s)-rel-2-phenylcyclopropanamine
CHEBI:94631
trans-(1r,2s)-2-phenylcyclopropan-1-amine
(rel)-tranylcypromine
DTXSID201015773
NCGC00015848-07
(1r,2s)(c)\\rel-2(c)\\phenylcyclopropan(c)\\1(c)\\amine
AMY35672
NCGC00015848-09
BS-50045
A902847
A857918
nsc789036
nsc-789036
mfcd00865363
mfcd00001302
(1r,2s)-2-phenylcyclopropylamine
CS-0099373
EN300-197006
rac-(1r,2s)-2-phenylcyclopropan-1-amine
EN300-253001
tranylcyprominum (inn-latin)
tranilcipromina (inn-spanish)
(+-)-trans-2-phenylcyclopropylamine
n06af04
dtxcid501473942
skf 385'
tranylcypromin
chebi:9652

Research Excerpts

Overview

Tranylcypromine (TCP) is an effective antidepressant from the class of monoamine oxidase inhibitors and is structurally related to amphetamine. It is an important chemical template for developing irreversible LSD1 inhibitors, representing a major chemotype of clinical candidates.

ExcerptReferenceRelevance
"Tranylcypromine (TCP) is an important chemical template for developing irreversible LSD1 inhibitors, representing a major chemotype of clinical candidates."( Design, synthesis and in vitro/in vivo anticancer activity of tranylcypromine-based triazolopyrimidine analogs as novel LSD1 inhibitors.
Li, L; Li, X; Li, Z; Ma, H; Ma, J; Ma, L; Qiao, Y; Song, J; Su, Y; Sun, Y; Wang, P; Xie, Z; Yuan, Y; Zhang, F; Zhang, X; Zhang, Z, 2023
)
1.87
"Tranylcypromine is an effective antidepressant from the class of monoamine oxidase inhibitors and is structurally related to amphetamine. "( Discrimination Between Drug Abuse and Medical Therapy: Case report of a tranylcypromine overdose-related fatality.
Akhgari, M; Etemadi-Aleagha, A; Ghasemi, A; Jokar, F, 2017
)
2.13
"Tranylcypromine (TCP) is an antidepressant originally known to target the monoamine oxidases A and B (MAO-A and MAO-B), which are structurally related to LSD1."( Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Gunosewoyo, H; Ji, YY; Li, J; Lin, SD; Su, MB; Tang, J; Wang, YJ; Yang, F; Yu, LF; Zhang, W; Zhou, YB, 2017
)
1.59
"Tranylcypromine is a non-selective irreversible MAOI used in refractory depression and bipolar disorder."( Myocardial Injury from Tranylcypromine-Induced Hypertensive Crisis Secondary to Excessive Tyramine Intake.
Kenney, A; Salter, M, 2018
)
1.51
"Tranylcypromine (TCP) is a non-selective and irreversible monoamine oxidase inhibitor and an effective agent in the treatment of major depression. "( Intoxications with the monoamine oxidase inhibitor tranylcypromine: an analysis of fatal and non-fatal events.
Freudenmann, RW; Gahr, M; Kölle, MA; Schönfeldt-Lecuona, C, 2013
)
2.08
"Tranylcypromine is a non-selective inhibitor of monamine oxidase which also inhibits the reuptake of norepinephrine. "( Abnormal pregnancy outcome associated with high-dose maternal tranylcypromine therapy: Case report and literature review.
Hill, M; Kennedy, D; Ritchie, HE; Webster, WS, 2017
)
2.14
"Tranylcypromine (TCP) is an effective antidepressant with a complex pharmacological profile and a relevant risk of abuse and dependence. "( Withdrawal and discontinuation phenomena associated with tranylcypromine: a systematic review.
Freudenmann, RW; Gahr, M; Kölle, MA; Schönfeldt-Lecuona, C, 2013
)
2.08
"Tranylcypromine is a rapid, relatively safe, and dramatically effective treatment for anergic depression."( A double-blind study of tranylcypromine treatment of major anergic depression.
Fuchs, CZ; Himmelhoch, JM; Symons, BJ, 1982
)
1.29
"Tranylcypromine (TCP) is a commercially available antidepressant drug, and recent literature reports suggest that high doses of this drug may be particularly effective in treating refractory depression. "( Comparisons of the actions of high and low doses of the MAO inhibitor tranylcypromine on 5-HT2 binding sites in rat cortex.
Baker, GB; Goodnough, DB, 1994
)
1.97
"Tranylcypromine (TCP) is a monoamine oxidase inhibitor used extensively in the treatment of patients with reactive depression. "( Tranylcypromine induced hypertension is not mediated by the inhibition of prostacyclin synthesis.
Einzig, S; Rao, GH; Reddy, KR; White, JG, 1979
)
3.15
"Tranylcypromine is a safe, rapidly acting, very effective antidepressant and appears to be the drug of choice in patients with agitated depressions."( Tranylcypromine (Parnate)--a study of 1000 patients with severe agitated depressions.
Lesse, S, 1978
)
2.42

Effects

Tranylcypromine has multiple pharmacological effects, increasing monoamine release for a few hours immediately after its administration and blocking MAO activity for several days. The (+)-isomer in particular is effective as adjuvant anti-parkinsonian therapy.

ExcerptReferenceRelevance
"Tranylcypromine has been recommend as an option for therapy-resistant depressive and anxiety disorders. "( [Tranylcypromine for chronic therapy-resistant agoraphobia with panic disorder and recurrent depressive disorder].
Boerner, RJ; Lühring, F, 2010
)
2.71
"Tranylcypromine has multiple pharmacological effects, increasing monoamine release for a few hours immediately after its administration and blocking MAO activity for several days."( Serotonergic mechanism underlying tranylcypromine enhancement of nicotine self-administration.
Belluzzi, JD; Leslie, FM; Villégier, AS, 2011
)
1.37
"The tranylcypromine stereoisomers have been investigated in a series of comparative trials in Parkinsons' disease and the results indicate that doses below 3 mg/day, of the (+)-isomer in particular, are effective as adjuvant anti-parkinsonian therapy. "( Tranylcypromine isomers and Parkinson's disease: new aspects of an old drug.
Reynolds, GP; Riederer, P; Sandler, M, 1981
)
2.26

Actions

Tranylcypromine (Tra) could inhibit the metabolism of drug as well. It did, however, produce concentration-dependent enhancement of HMBA- and NADAH-induced differentiation.

ExcerptReferenceRelevance
"Tranylcypromine (Tra) could inhibit the metabolism of drug as well."( [Metabolic kinetics of MN9202 in Beagle dog liver microsomes].
Liu, ZG; Mei, QB; Yang, TH; Yang, ZF; Zhou, SY, 2005
)
1.05
"Tranylcypromine did, however, produce concentration-dependent enhancement of HMBA- and NADAH-induced differentiation."( Effects of the monoamine oxidase inhibitor, tranylcypromine, on induction of HL60 cell differentiation by hexamethylene bisacetamide and N-acetyl-1,6-diaminohexane.
Callery, PS; Egorin, MJ; Schimpff, EC; Snyder, SW; Zuhowski, EG, 1990
)
1.26

Treatment

Tranylcypromine (TCP) pretreatment was found to accelerate the tremorogenic activity of tremorine in rats. Tranylcy Promine significantly increased CB(1) receptor binding density in the prefrontal cortex and hippocampus, but not in the hypothalamus.

ExcerptReferenceRelevance
"Tranylcypromine treatment significantly increased CB(1) receptor binding density in the prefrontal cortex and hippocampus, but not in the hypothalamus."( Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents.
Gorzalka, BB; Hill, MN; Hillard, CJ; Ho, WS, 2008
)
1.33
"Tranylcypromine pretreatment combined with nicotine (0.2 mg/kg) significantly increased locomotor activity and time spent in the center of the open field."( Age influences the effects of nicotine and monoamine oxidase inhibition on mood-related behaviors in rats.
Belluzzi, JD; Gallager, B; Heston, J; Leslie, FM; Villégier, AS, 2010
)
1.08
"Tranylcypromine treatment leads to an up-regulation of GABA(B)-receptors and modulates the phospholipid metabolism, which is essential for normal brain function."( Tranylcypromine: new perspectives on an "old" drug.
Bleich, S; Frieling, H, 2006
)
2.5
"Tranylcypromine-treated patients showed no significant changes in ECG parameters."( Electrocardiographic effects of tranylcypromine vs. amitriptyline.
O'Leary, J; Palmer, R; Razani, J; Rebal, R; White, K, 1983
)
1.27
"Tranylcypromine treatment at the dose 5 mg/kg b."( Validation of aversion towards open space and height as a measure of anxiety in the genetically based animal model of depression.
Golda, V; Petr, R, 1990
)
1
"In tranylcypromine-pretreated rats, 3-MT was dose-dependently reduced and increased by apomorphine (0.01-5 mg/kg i.p.) and BRL 34778 (0.1-5 mg/kg i.p.), respectively."( A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detection. Studies with drugs which alter dopamine metabolism in the brain.
Buckett, WR; Frankland, AT; Heal, DJ, 1990
)
0.79
"Tranylcypromine (TCP) pretreatment was found to accelerate the tremorogenic activity of tremorine in rats. "( The role of adrenergic mechanism in tremorine-induced tremors in rats: antitremor effect of beta-adrenoceptor antagonists.
Paul, V,
)
1.57
"Treatment with tranylcypromine and pargyline, which are potent inhibitors of LSD1, prevented IL-1β-induced H3K9 demethylation at the mPGES-1 promoter and expression of mPGES-1."( Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1β-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes.
Afif, H; Benderdour, M; El Mansouri, FE; Fahmi, H; Kapoor, M; Martel-Pelletier, J; Nebbaki, SS; Pelletier, JP, 2014
)
0.74
"Pretreatment with tranylcypromine resulted in a threefold increase in the mean value for Ra, which was due to increased secretion of NE into the CSF."( Apparent turnover of norepinephrine in the intact rat brain estimated from its rate of appearance in the cerebroventricular compartment.
Barkai, AI; Kowalik, S; Levitt, M, 1983
)
0.59
"Pretreatment with tranylcypromine, an inhibitor of prostacyclin biosynthesis, did not block the prostaglandin E and F increases, but did block the oil stimulated DCR."( Uterine prostaglandin levels following stimulation of the decidual cell reaction: effects of indomethacin and tranylcypromine.
Baggett, B; Jonsson, HT; Ledford, BE; Rankin, JC, 1979
)
0.8

Toxicity

ExcerptReferenceRelevance
" No adverse reactions were reported, including hypertensive and hyperpyrexic crises."( The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors.
Kahn, D; Opler, LA; Silver, JM, 1989
)
0.28
"84 per patients) and a total of 125 side effect reports were noted in 39 of 42 phenelzine patients (2."( Common side effects associated with monoamine oxidase inhibitors.
Froese, C; Keller, FD; Remick, RA, 1989
)
0.28
"All 10 patients tolerated the addition of an MAOI well, and mean self-rated side effect scores did not change significantly."( Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.
Ketter, TA; Parekh, PI; Post, RM; Worthington, K, 1995
)
0.29
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" In contrast, fluoxetine revealed a toxic effect and exhibited an additive effect against the toxicity of MPP(+)."( Antidepressants reveal differential effect against 1-methyl-4-phenylpyridinium toxicity in differentiated PC12 cells.
Han, YS; Lee, CS, 2009
)
0.35

Pharmacokinetics

plasma drug levels were measured hourly from 5-8 hours after a tranylcypromine dose. Time-efficacy calculations showed the maximal pharmacodynamic effect of pirlindol in the 4th to 6th hour. The assay was found to be applicable for routine analyses in a preliminary pharmacokinetic study.

ExcerptReferenceRelevance
" The assay was found to be applicable for routine analyses in a preliminary pharmacokinetic study, in which an oral dose of 20 mg racemic tranylcypromine sulfate was administered to three healthy volunteers."( Enantiospecific high-performance liquid chromatographic assay with fluorescence detection for the monoamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies.
Hahn, G; Langguth, P; Möhrke, W; Mutschler, E; Spahn-Langguth, H, 1992
)
0.69
" After oral administration of a tranylcypromine dose, plasma drug levels were measured hourly from 5-8 hours (N = 16) or 0-8 hours (N = 10) postdose, and pharmacokinetic parameters were calculated."( Plasma tranylcypromine: relationship to pharmacokinetic variables and clinical antidepressant actions.
Edwards, DJ; Himmelhoch, JM; Knopf, S; Mallinger, AG; Thase, ME, 1990
)
1.02
" Time-efficacy calculations showed the maximal pharmacodynamic effect of pirlindol in the 4th to 6th hour, of 75 mg imipramine in the 2nd hour, of 20 mg tranylcypromine in the 4th hour and of 150 mg nomifensine in the 6th hour."( [Classification and determination of the pharmacodynamics of a new tetracyclic antidepressive agent, pirlindol, using pharmaco-EEG and psychometry].
Grünberger, L; Linzmayer, L; Saletu, B; Stöhr, H; Wittek, R, 1983
)
0.46

Compound-Compound Interactions

The study was carried out to evaluate the efficacy and safety of prescribing tranylcypromine (TCP) singly and in combination with amitriptyline (AMI) Previously, we showed that ATRA can induce myeloid differentiation in AML blasts.

ExcerptReferenceRelevance
"Eight hundred fifty-one severely depressed patients were treated on an out-patient basis over a twenty-year period with psychotherapy in combination with antidepressant drug therapy."( Psychotherapy in combination with antidepressant drugs in severely depressed out-patients--20-year evaluation.
Lesse, S, 1978
)
0.26
"Data on blood pressure was extracted from the findings of a 6-week double-blind study that was carried out to evaluate the efficacy and safety of prescribing tranylcypromine (TCP) singly and in combination with amitriptyline (AMI)."( Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline.
McKeon, P; O'Brien, S; O'Flaherty, A; O'Regan, M; Patel, R, 1992
)
0.78
" Previously, we showed that ATRA in combination with Lysine-specific demethylase 1 (LSD1) inhibition by tranylcypromine (TCP) can induce myeloid differentiation in AML blasts."( A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
Besenbeck, B; Binder, M; Bornhäuser, M; Burhenne, J; Dugas, M; Foerster, KI; Göllner, S; Göthert, JR; Haefeli, WE; Lenz, G; Mikesch, JH; Müller, LP; Müller-Tidow, C; Mundmann, P; Noppeney, R; Pabst, C; Platzbecker, U; Röllig, C; Schlenk, RF; Schliemann, C; Serve, H; Wass, M; Wermke, M, 2021
)
1.07

Bioavailability

ExcerptReferenceRelevance
"The present study was designed to investigate the involvement of monoaminergic system(s) in the antidepressant activity of curcumin and the effect of piperine, a bioavailability enhancer, on the bioavailability and biological effects of curcumin."( Antidepressant activity of curcumin: involvement of serotonin and dopamine system.
Bhutani, MK; Bishnoi, M; Kulkarni, SK, 2008
)
0.35

Dosage Studied

Thirty newly hospitalized patients with RDC major or minor depressive disorder were randomly assigned to open treatment. Pargyline and tranylcypromine shifted the dose-response curves for tyramine and beta-phenylethylamine, but not serotonin, to the left, indicating inhibition of type B MAO.

ExcerptRelevanceReference
" Superfusion of the arterial segment with PGI2 demonstrates a dose-response related inhibition of ADP-induced thrombosis."( The role of prostaglandins in platelet-vessel wall interaction.
Andries, R; Bourgain, RH; Finne, E, 1979
)
0.26
"Patients who failed to respond to sustained, adequate treatment with the tricyclic imipramine (mean maximum dosage = 260 mg/day) and interpersonal psychotherapy were withdrawn from imipramine and treated in a standardized, but open-label 6-week trial with either phenelzine (N = 4; 60 mg/day) or tranylcypromine (N = 36; mean = 38."( Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors.
Frank, E; Hamer, T; Kupfer, DJ; Mallinger, AG; Thase, ME, 1992
)
0.46
" The dosage was 150-300 mg moclobemide and 15-30 mg tranylcypromine daily."( Moclobemide versus tranylcypromine in the treatment of depression.
Moll, E; Rossel, L, 1990
)
0.86
" In "endogenous" depression, a statistically significant linear dose-response relationship was found in all the efficacy variables assessed."( Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
Delini-Stula, A; Heath, WR; Schiwy, W, 1989
)
0.28
" Isolated rings (circular preparations) obtained from rat thoracic aortae responded to increasing concentrations of NE with dose-dependent tonic enhancement, not significantly affected by the presence of indomethacin (10(-6)M); whereas, preincubation with phentolamine (10(-6)M), yohimbine (10(-7)M) or prazosin (10(-8)M), shifted significantly to the right points of the positive inotropic dose-response curve for NE."( Possible prostacyclin involvement on disparate tonic responses to "in vitro" norepinephrine in circular and in longitudinal preparations from rat thoracic aorta.
Chaud, M; Franchi, AM; Gimeno, AL; Gimeno, MA, 1987
)
0.27
" Both CE-TCP and TCP inhibited MAO-A and MAO-B, with maximum inhibition occurring 60 min after CE-TCP dosing and 30 min after dosing with TCP, times at which brain concentrations of CE-TCP and TCP were at the maximum."( N-(2-cyanoethyl)tranylcypromine, a potential prodrug of tranylcypromine: its disposition and interaction with catecholamine neurotransmitters in brain.
Baker, GB; Coutts, RT; Nazarali, AJ; Wong, TF, 1987
)
0.62
" Pargyline and tranylcypromine shifted the dose-response curves for tyramine and beta-phenylethylamine, but not serotonin, to the left, indicating inhibition of type B MAO."( Some cardiovascular effects of monoamine oxidase inhibitors in unanaesthetized rats.
Huston, V; Marwood, JF; Wall, KT,
)
0.48
" Effects of TCP on concentrations of DA and NA varied, depending on the brain area investigated and the dosage used."( Regional concentrations of cerebral amines: effects of tranylcypromine and phenelzine.
Baker, GB; Calverly, DG; Dewhurst, WG; McKim, RH, 1983
)
0.51
" (+)-TCP at high dosage (30 mg/kg) decreased brain levels of 5-HIAA, whereas (-)-TCP failed to affect 5-HIAA levels."( Stereoselective effect of tranylcypromine enantiomers on brain serotonin.
Petersen, HN; Smith, DF, 1982
)
0.56
"Sixty patients meeting DSM-III criteria for major depression were assigned randomly to double-blind treatment for four weeks according to fixed-dosage steps with (1) amitriptyline hydrochloride alone, up to a maximum dosage of 300 mg/day; (2) tranylcypromine alone, up to 40 mg/day; or (3) the combination of amitriptyline hydrochloride, up to 150 mg/day, and tranylcypromine, up to 20 mg/day."( The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial.
Palmer, R; Razani, J; Rebal, R; Simpson, G; Sloane, RB; White, J; White, KL, 1983
)
0.7
" Its pharmaco-EEG profile, especially after higher dosage (150 and 225 mg), was characterized by a decrease in delta and theta activity, an increase in alpha activity and a delta and theta activity, an increase in alpha activity and a decrease in beta activity, as well as by an attenuation of the average frequency and frequency deviation and a trend towards an augmentation of the amplitude and amplitude variability."( [Classification and determination of the pharmacodynamics of a new tetracyclic antidepressive agent, pirlindol, using pharmaco-EEG and psychometry].
Grünberger, L; Linzmayer, L; Saletu, B; Stöhr, H; Wittek, R, 1983
)
0.27
" Only the animals dosed with barbital exhibited severe withdrawal signs such as spontaneous withdrawal convulsions."( Effects of propranolol on barbital dependence formation and withdrawal signs.
Hiramori, T; Nakao, K; Tagashira, E; Urano, T; Yanaura, S, 1983
)
0.27
" These results suggest that molindone in low dosage may be helpful in the management of refractory depression and may have the further advantage of producing a more rapid response to treatment with fewer disabling side effects."( Comparison of molindone and tranylcypromine in the treatment of refractory depression.
Dennis, JL; Kellams, JJ; Milstein, V; Small, JG,
)
0.43
" The method has been applied to the measurement of tranylcypromine levels in plasma and urine from both healthy volunteers and from psychiatric patients receiving a therapeutic dosage of the drug."( Determination of tranylcypromine in human plasma and urine using high-resolution gas--liquid chromatography with nitrogen-sensitive detection.
Bailey, E; Barron, EJ, 1980
)
0.85
"Thirty newly hospitalized patients with RDC major or minor depressive disorder were randomly assigned to open treatment according to fixed dosage steps with 1) amitriptyline alone, up to a maximum dose of 300 mg/day; 2) tranylcypromine alone, up to a maximum dose of 40 mg/day; or 3) the combination of amitriptyline, up to 150 mg/day, and tranylcypromine, up to 20 mg/day."( Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.
Boyd, JL; Pistole, T; White, K, 1980
)
0.45
" The results of the trial are compared with other trials of monoamine oxidase inhibitors in this patient group and the possible reasons for the lack of a clear dose-response relationship are discussed."( Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine.
Bellaire, J; Heimann, H; Laux, G; Möller, HJ; Volz, HP, 1994
)
0.5
" In keeping with previous data obtained with other sigma receptor ligands, low doses of sertraline and of clorgyline potentiated selectively with a bell-shaped dose-response curve the effect of N-methyl-D-aspartate (NMDA) on pyramidal neurons in the CA3 region of the rat dorsal hippocampus."( Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands.
Bergeron, R; De Montigny, C; Debonnel, G, 1993
)
0.29
" Adequate stable anesthesia was achieved in reduced dosage of conventional anesthesiological agents."( [Use of nonopiate agents for anesthesia in ENT patients at high surgical-anesthesiological risk].
Akopian, RG; Daĭkhes, NA; Davudov, KhSh; Gur'ianov, VA; Kokliaeva, NV; Kuĭian, SM; Nazhmudinov, II; Pogosov, VS; Riazanov, VB; Tiukov, VL, 1998
)
0.3
" Dose-response curves were established for the increase in BP induced by tyramine (5-200 mg/kg) administered orally via a naso-pharyngeal tube."( Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits.
Gorodetsky, E; Gross, A; Wang, RH; Weinreb, O; Weinstock, M; Youdim, MB, 2002
)
0.31
" A comparison of citalopram and fluoxetine pharmacokinetics in the same animal and at the same dosage (1 mg/kg) showed that citalopram SERT occupancy and plasma half-lives were 9 times and 14 times shorter, respectively, than those of fluoxetine and norfluoxetine."( [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats.
Ginovart, N; Houle, S; Hussey, D; Meyer, JH; Wilson, AA, 2003
)
0.32
"The pharmacokinetics of the two enantiomers of tranylcypromine were evaluated in six healthy subjects after oral dosage of the racemate (20 mg of the sulphate) and the single enantiomers (10 mg of the sulphate) using an enantiospecific assay."( The pharmacokinetics of tranylcypromine enantiomers in healthy subjects after oral administration of racemic drug and the single enantiomers.
Hahn, G; Langguth, P; Möhrke, W; Mutschler, E; Spahn-Langguth, H; Weber-Grandke, H, 1993
)
0.85
" Dosing of TCP and the use of multiple psychotropic comedications indicate a high-intensity treatment."( Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
Adli, M; Bauer, M; Bschor, T; Janssen, G; Köberle, U; Pilhatsch, M; Ricken, R; Ulrich, S, 2008
)
0.57
"Our objective was to explore the dose-response relationship in patients with panic disorder and social anxiety disorder comorbidity (DSM-IV)."( Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder.
de-Melo-Neto, VL; Freire, RC; Grivet, LO; King, AL; Lopes, FL; Mezzasalma, MA; Nardi, AE; Nascimento, I; Rassi, A; Soares-Filho, GL; Valença, AM; Veras, AB; Versiani, M, 2010
)
0.63
" Therefore, rat urine taken after dosing with fluoxetine was screened in the same way."( Gas chromatography-mass spectrometry detection of a norfluoxetine artifact in hydrolyzed urine samples may falsely indicate tranylcypromine ingestion.
Maurer, HH; Meyer, MR; Schwaninger, AE,
)
0.34
" The average dosage related to TCP-intoxication was 677 mg."( Intoxications with the monoamine oxidase inhibitor tranylcypromine: an analysis of fatal and non-fatal events.
Freudenmann, RW; Gahr, M; Kölle, MA; Schönfeldt-Lecuona, C, 2013
)
0.64
" By study phase, Eight of 27 (30%) patients remitted with initial dosing of tranylcypromine up to 60 mg/d, 6/18 (33%) remitted with above PDR dosing of tranylcypromine up to 120 mg/d, and 1/6 (17%) to adding dextroamphetamine."( How treatable is refractory depression?
Deliyannides, DA; McGrath, PJ; Stewart, JW, 2014
)
0.63
" The results show that (1) tranylcypromine (TCP), a known MAO inhibitor, increases sensitivity to the primary reinforcing effects of nicotine, shifting the dose-response curve for nicotine to the left, (2) inhibition of MAO-A, but not MAO-B, increases low-dose nicotine self-administration, (3) partial MAO-A inhibition, to the degree observed in chronic cigarette smokers, also increases low-dose nicotine self-administration, and (4) TCP decreases the threshold nicotine dose required for reinforcement enhancement."( Effects of Monoamine Oxidase Inhibition on the Reinforcing Properties of Low-Dose Nicotine.
Cwalina, SN; Donny, EC; Murphy, SE; Onimus, MJ; Rupprecht, LE; Smith, TT; Sved, AF, 2016
)
0.73
" The dose-response relationship calls for caution with higher doses of tranylcypromine."( Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.
Bauer, M; Findeis, H; Ludwig, VM; Ritter, P; Rucker, J; Sauer, C; Young, AH, 2021
)
1.07
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
2-phenylcyclopropan-1-amineA member of the class of cyclopropanes carrying amino and phenyl substituents at positions 1 and 2 respectively.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (63)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency5.01190.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency5.01190.025120.237639.8107AID886
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency31.62280.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency12.58930.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency39.81070.00636.904339.8107AID883
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency7.94330.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency17.78280.00106.000935.4813AID943
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency39.81070.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific histone demethylase 1AHomo sapiens (human)IC50 (µMol)31.70230.00312.16029.6000AID1274609; AID1282330; AID1368695; AID1388927; AID1389949; AID1515260; AID1536068; AID1572509; AID1669136; AID1702767; AID1737495; AID1773372; AID604027
Lysine-specific histone demethylase 1AHomo sapiens (human)Ki208.22000.00962.54425.6000AID1755566; AID1854419; AID603121; AID603122; AID639764
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Cytochrome P450 1A1Homo sapiens (human)IC50 (µMol)6.20000.00791.24789.9000AID1617365
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)13.10000.00011.774010.0000AID1614065; AID1617365
Cytochrome P450 2E1Homo sapiens (human)IC50 (µMol)6.20000.01401.68726.2000AID1617365
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)3.58500.00011.753610.0000AID1617365; AID1622671
Cytochrome P450 2C8Homo sapiens (human)IC50 (µMol)6.20000.00081.88487.9000AID1617365
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)6.20000.00002.015110.0000AID1617365
Cytochrome P450 2A6Homo sapiens (human)IC50 (µMol)2.71330.00443.889510.0000AID1617365; AID1622671
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)3.38000.00002.800510.0000AID1572512; AID1617365
Cytochrome P450 4B1Homo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)IC50 (µMol)0.07800.00040.764912.5000AID1274608
Cytochrome P450 2B6Homo sapiens (human)IC50 (µMol)9.84000.00113.418610.0000AID1614067; AID1617365; AID318312
Cytochrome P450 3A5Homo sapiens (human)IC50 (µMol)6.20000.00330.70736.2000AID1617365
Cytochrome P450 2A7Homo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)IC50 (µMol)0.29000.00071.979812.5000AID1274607
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)5.68810.00002.37899.7700AID1282332; AID1368696; AID1382511; AID1388929; AID1536071; AID1572511; AID1575524; AID366634
Amine oxidase [flavin-containing] AHomo sapiens (human)Ki102.00000.00192.379710.0000AID1755621; AID639766
Cytochrome P450 3A7Homo sapiens (human)IC50 (µMol)6.20000.01402.75806.2000AID1617365
Cytochrome P450 2F1Homo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)5.07620.00001.89149.5700AID1282333; AID1368697; AID1382512; AID1388930; AID1536072; AID1572512; AID1575526; AID366635
Amine oxidase [flavin-containing] BHomo sapiens (human)Ki16.00000.00061.777110.0000AID1755622; AID639768
Cytochrome P450 2C18Homo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)8.36890.00002.398310.0000AID1614065; AID1617365; AID1617368; AID1721036; AID1739439; AID1756367; AID1813644; AID1863228; AID318314
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)6.20000.01202.53129.4700AID1617365
Cytochrome P450 4F2Homo sapiens (human)IC50 (µMol)6.20001.60004.26676.2000AID1617365
Cytochrome P450 4F8Homo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Cytochrome P450 4A11Homo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Cytochrome P450 4F3Homo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)6.20000.00130.86969.9000AID1617365
Cytochrome P450 2A13Homo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Cytochrome P450 4A22Homo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)Ki6.20000.00241.10509.3000AID1681677
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki1.80000.00000.338510.0000AID1681676
Vitamin D 25-hydroxylaseHomo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Cytochrome P450 2U1Homo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Cytochrome P450 2W1Homo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Cytochrome P450 2S1Homo sapiens (human)IC50 (µMol)6.20006.20006.20006.2000AID1617365
Cytochrome P450 3A43 Homo sapiens (human)IC50 (µMol)6.20000.01402.75806.2000AID1617365
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Trace amine-associated receptor 1Homo sapiens (human)EC50 (µMol)1.51000.01501.41437.1900AID341210
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (218)

Processvia Protein(s)Taxonomy
regulation of double-strand break repair via homologous recombinationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of protein ubiquitinationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of protein localizationLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to UVLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to gamma radiationLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair-dependent chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuroblast proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
protein demethylationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuron projection developmentLysine-specific histone demethylase 1AHomo sapiens (human)
cerebral cortex developmentLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
neuron maturationLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cell sizeLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
guanine metabolic processLysine-specific histone demethylase 1AHomo sapiens (human)
muscle cell developmentLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific histone demethylase 1AHomo sapiens (human)
response to fungicideLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to cAMPLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neural precursor cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of stem cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1A1Homo sapiens (human)
response to hypoxiaCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
lipid hydroxylationCytochrome P450 1A1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid metabolic processCytochrome P450 1A1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A1Homo sapiens (human)
amine metabolic processCytochrome P450 1A1Homo sapiens (human)
response to nematodeCytochrome P450 1A1Homo sapiens (human)
response to herbicideCytochrome P450 1A1Homo sapiens (human)
ethylene metabolic processCytochrome P450 1A1Homo sapiens (human)
coumarin metabolic processCytochrome P450 1A1Homo sapiens (human)
flavonoid metabolic processCytochrome P450 1A1Homo sapiens (human)
response to iron(III) ionCytochrome P450 1A1Homo sapiens (human)
insecticide metabolic processCytochrome P450 1A1Homo sapiens (human)
dibenzo-p-dioxin catabolic processCytochrome P450 1A1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
response to foodCytochrome P450 1A1Homo sapiens (human)
response to lipopolysaccharideCytochrome P450 1A1Homo sapiens (human)
response to vitamin ACytochrome P450 1A1Homo sapiens (human)
response to immobilization stressCytochrome P450 1A1Homo sapiens (human)
vitamin D metabolic processCytochrome P450 1A1Homo sapiens (human)
retinol metabolic processCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
9-cis-retinoic acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
camera-type eye developmentCytochrome P450 1A1Homo sapiens (human)
nitric oxide metabolic processCytochrome P450 1A1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1A1Homo sapiens (human)
digestive tract developmentCytochrome P450 1A1Homo sapiens (human)
tissue remodelingCytochrome P450 1A1Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A1Homo sapiens (human)
response to hyperoxiaCytochrome P450 1A1Homo sapiens (human)
maternal process involved in parturitionCytochrome P450 1A1Homo sapiens (human)
hepatocyte differentiationCytochrome P450 1A1Homo sapiens (human)
cellular response to copper ionCytochrome P450 1A1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCytochrome P450 1A1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1A1Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2E1Homo sapiens (human)
lipid hydroxylationCytochrome P450 2E1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2E1Homo sapiens (human)
steroid metabolic processCytochrome P450 2E1Homo sapiens (human)
response to bacteriumCytochrome P450 2E1Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2E1Homo sapiens (human)
carbon tetrachloride metabolic processCytochrome P450 2E1Homo sapiens (human)
benzene metabolic processCytochrome P450 2E1Homo sapiens (human)
4-nitrophenol metabolic processCytochrome P450 2E1Homo sapiens (human)
halogenated hydrocarbon metabolic processCytochrome P450 2E1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2E1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2E1Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
fatty acid metabolic processCytochrome P450 4B1Homo sapiens (human)
biphenyl metabolic processCytochrome P450 4B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2B6Homo sapiens (human)
steroid metabolic processCytochrome P450 2B6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2B6Homo sapiens (human)
cellular ketone metabolic processCytochrome P450 2B6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2B6Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A5Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A5Homo sapiens (human)
steroid metabolic processCytochrome P450 3A5Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A5Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A5Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A5Homo sapiens (human)
retinol metabolic processCytochrome P450 3A5Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A5Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A5Homo sapiens (human)
oxidative demethylationCytochrome P450 3A5Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A7Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A7Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A7Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A7Homo sapiens (human)
steroid biosynthetic processCytochrome P450 3A7Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A7Homo sapiens (human)
steroid metabolic processCytochrome P450 3A7Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A7Homo sapiens (human)
retinol metabolic processCytochrome P450 3A7Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A7Homo sapiens (human)
oxidative demethylationCytochrome P450 3A7Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2F1Homo sapiens (human)
response to toxic substanceCytochrome P450 2F1Homo sapiens (human)
naphthalene catabolic processCytochrome P450 2F1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2F1Homo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C18Homo sapiens (human)
retinol metabolic processCytochrome P450 2C18Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C18Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2C18Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C18Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
very long-chain fatty acid metabolic processCytochrome P450 4F2Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 4F2Homo sapiens (human)
renal water homeostasisCytochrome P450 4F2Homo sapiens (human)
pressure natriuresisCytochrome P450 4F2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 4F2Homo sapiens (human)
leukotriene metabolic processCytochrome P450 4F2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 4F2Homo sapiens (human)
blood coagulationCytochrome P450 4F2Homo sapiens (human)
regulation of blood pressureCytochrome P450 4F2Homo sapiens (human)
fatty acid omega-oxidationCytochrome P450 4F2Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 4F2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 4F2Homo sapiens (human)
negative regulation of icosanoid secretionCytochrome P450 4F2Homo sapiens (human)
positive regulation of icosanoid secretionCytochrome P450 4F2Homo sapiens (human)
leukotriene B4 catabolic processCytochrome P450 4F2Homo sapiens (human)
vitamin E metabolic processCytochrome P450 4F2Homo sapiens (human)
menaquinone catabolic processCytochrome P450 4F2Homo sapiens (human)
phylloquinone catabolic processCytochrome P450 4F2Homo sapiens (human)
vitamin K catabolic processCytochrome P450 4F2Homo sapiens (human)
sodium ion homeostasisCytochrome P450 4F2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 4F2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 4F8Homo sapiens (human)
prostaglandin metabolic processCytochrome P450 4F8Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 4A11Homo sapiens (human)
renal water homeostasisCytochrome P450 4A11Homo sapiens (human)
pressure natriuresisCytochrome P450 4A11Homo sapiens (human)
fatty acid metabolic processCytochrome P450 4A11Homo sapiens (human)
leukotriene metabolic processCytochrome P450 4A11Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 4A11Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 4A11Homo sapiens (human)
oxylipin biosynthetic processCytochrome P450 4A11Homo sapiens (human)
positive regulation of icosanoid secretionCytochrome P450 4A11Homo sapiens (human)
leukotriene B4 catabolic processCytochrome P450 4A11Homo sapiens (human)
sodium ion homeostasisCytochrome P450 4A11Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 4A11Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 4A11Homo sapiens (human)
kidney developmentCytochrome P450 4A11Homo sapiens (human)
lauric acid metabolic processCytochrome P450 4A11Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 4A11Homo sapiens (human)
icosanoid metabolic processCytochrome P450 4F3Homo sapiens (human)
leukotriene metabolic processCytochrome P450 4F3Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 4F3Homo sapiens (human)
leukotriene B4 catabolic processCytochrome P450 4F3Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A13Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 2A13Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A13Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A13Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 4A22Homo sapiens (human)
lipid hydroxylationCytochrome P450 4A22Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 4A22Homo sapiens (human)
lauric acid metabolic processCytochrome P450 4A22Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 4A22Homo sapiens (human)
kidney developmentCytochrome P450 4A22Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 4A22Homo sapiens (human)
vitamin metabolic processVitamin D 25-hydroxylaseHomo sapiens (human)
response to cesium ionVitamin D 25-hydroxylaseHomo sapiens (human)
response to ionizing radiationVitamin D 25-hydroxylaseHomo sapiens (human)
calcitriol biosynthetic process from calciolVitamin D 25-hydroxylaseHomo sapiens (human)
vitamin D metabolic processVitamin D 25-hydroxylaseHomo sapiens (human)
xenobiotic metabolic processVitamin D 25-hydroxylaseHomo sapiens (human)
organic acid metabolic processVitamin D 25-hydroxylaseHomo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2U1Homo sapiens (human)
cytochrome metabolic processCytochrome P450 2U1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2U1Homo sapiens (human)
organic acid metabolic processCytochrome P450 2U1Homo sapiens (human)
phospholipid metabolic processCytochrome P450 2W1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2W1Homo sapiens (human)
retinoic acid catabolic processCytochrome P450 2W1Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 2W1Homo sapiens (human)
cytochrome metabolic processCytochrome P450 2W1Homo sapiens (human)
organic acid metabolic processCytochrome P450 2W1Homo sapiens (human)
G protein-coupled receptor signaling pathwayTrace amine-associated receptor 1Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2S1Homo sapiens (human)
prostaglandin metabolic processCytochrome P450 2S1Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2S1Homo sapiens (human)
cytochrome metabolic processCytochrome P450 2S1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2S1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2S1Homo sapiens (human)
cytochrome metabolic processCytochrome P450 3A43 Homo sapiens (human)
steroid metabolic processCytochrome P450 3A43 Homo sapiens (human)
oxidative demethylationCytochrome P450 3A43 Homo sapiens (human)
negative regulation of DNA-templated transcriptionREST corepressor 3Homo sapiens (human)
regulation of transcription by RNA polymerase IIREST corepressor 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (99)

Processvia Protein(s)Taxonomy
telomeric DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
p53 bindingLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
oxidoreductase activityLysine-specific histone demethylase 1AHomo sapiens (human)
enzyme bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear receptor coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
identical protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
MRF bindingLysine-specific histone demethylase 1AHomo sapiens (human)
flavin adenine dinucleotide bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
telomeric repeat-containing RNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
FAD-dependent H3K4me/H3K4me3 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
promoter-specific chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
iron ion bindingCytochrome P450 1A1Homo sapiens (human)
protein bindingCytochrome P450 1A1Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donorsCytochrome P450 1A1Homo sapiens (human)
flavonoid 3'-monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxygen bindingCytochrome P450 1A1Homo sapiens (human)
enzyme bindingCytochrome P450 1A1Homo sapiens (human)
heme bindingCytochrome P450 1A1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 1A1Homo sapiens (human)
demethylase activityCytochrome P450 1A1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 1A1Homo sapiens (human)
aromatase activityCytochrome P450 1A1Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 2E1Homo sapiens (human)
iron ion bindingCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activityCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 2E1Homo sapiens (human)
4-nitrophenol 2-monooxygenase activityCytochrome P450 2E1Homo sapiens (human)
oxygen bindingCytochrome P450 2E1Homo sapiens (human)
enzyme bindingCytochrome P450 2E1Homo sapiens (human)
heme bindingCytochrome P450 2E1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 2E1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 2E1Homo sapiens (human)
aromatase activityCytochrome P450 2E1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2E1Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2E1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 4B1Homo sapiens (human)
iron ion bindingCytochrome P450 4B1Homo sapiens (human)
oxygen bindingCytochrome P450 4B1Homo sapiens (human)
heme bindingCytochrome P450 4B1Homo sapiens (human)
aromatase activityCytochrome P450 4B1Homo sapiens (human)
heterocyclic compound bindingCytochrome P450 4B1Homo sapiens (human)
monooxygenase activityCytochrome P450 2B6Homo sapiens (human)
iron ion bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-alpha-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
heme bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-beta-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2B6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2B6Homo sapiens (human)
monooxygenase activityCytochrome P450 3A5Homo sapiens (human)
iron ion bindingCytochrome P450 3A5Homo sapiens (human)
protein bindingCytochrome P450 3A5Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A5Homo sapiens (human)
oxygen bindingCytochrome P450 3A5Homo sapiens (human)
heme bindingCytochrome P450 3A5Homo sapiens (human)
aromatase activityCytochrome P450 3A5Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
iron ion bindingCytochrome P450 2A7Homo sapiens (human)
oxygen bindingCytochrome P450 2A7Homo sapiens (human)
aromatase activityCytochrome P450 2A7Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A7Homo sapiens (human)
heme bindingCytochrome P450 2A7Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A7Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
monooxygenase activityCytochrome P450 3A7Homo sapiens (human)
iron ion bindingCytochrome P450 3A7Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A7Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A7Homo sapiens (human)
oxygen bindingCytochrome P450 3A7Homo sapiens (human)
heme bindingCytochrome P450 3A7Homo sapiens (human)
all-trans retinoic acid 18-hydroxylase activityCytochrome P450 3A7Homo sapiens (human)
aromatase activityCytochrome P450 3A7Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A7Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A7Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A7Homo sapiens (human)
monooxygenase activityCytochrome P450 2F1Homo sapiens (human)
iron ion bindingCytochrome P450 2F1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2F1Homo sapiens (human)
oxygen bindingCytochrome P450 2F1Homo sapiens (human)
aromatase activityCytochrome P450 2F1Homo sapiens (human)
heme bindingCytochrome P450 2F1Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2F1Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
monooxygenase activityCytochrome P450 2C18Homo sapiens (human)
iron ion bindingCytochrome P450 2C18Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C18Homo sapiens (human)
oxygen bindingCytochrome P450 2C18Homo sapiens (human)
aromatase activityCytochrome P450 2C18Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2C18Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C18Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C18Homo sapiens (human)
heme bindingCytochrome P450 2C18Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
monooxygenase activityCytochrome P450 4F2Homo sapiens (human)
iron ion bindingCytochrome P450 4F2Homo sapiens (human)
protein bindingCytochrome P450 4F2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 4F2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 4F2Homo sapiens (human)
alkane 1-monooxygenase activityCytochrome P450 4F2Homo sapiens (human)
heme bindingCytochrome P450 4F2Homo sapiens (human)
leukotriene-B4 20-monooxygenase activityCytochrome P450 4F2Homo sapiens (human)
arachidonic acid omega-hydroxylase activityCytochrome P450 4F2Homo sapiens (human)
alpha-tocopherol omega-hydroxylase activityCytochrome P450 4F2Homo sapiens (human)
tocotrienol omega-hydroxylase activityCytochrome P450 4F2Homo sapiens (human)
aromatase activityCytochrome P450 4F2Homo sapiens (human)
20-hydroxy-leukotriene B4 omega oxidase activityCytochrome P450 4F2Homo sapiens (human)
20-aldehyde-leukotriene B4 20-monooxygenase activityCytochrome P450 4F2Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 4F2Homo sapiens (human)
monooxygenase activityCytochrome P450 4F8Homo sapiens (human)
iron ion bindingCytochrome P450 4F8Homo sapiens (human)
alkane 1-monooxygenase activityCytochrome P450 4F8Homo sapiens (human)
heme bindingCytochrome P450 4F8Homo sapiens (human)
aromatase activityCytochrome P450 4F8Homo sapiens (human)
monooxygenase activityCytochrome P450 4A11Homo sapiens (human)
iron ion bindingCytochrome P450 4A11Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 4A11Homo sapiens (human)
alkane 1-monooxygenase activityCytochrome P450 4A11Homo sapiens (human)
heme bindingCytochrome P450 4A11Homo sapiens (human)
leukotriene-B4 20-monooxygenase activityCytochrome P450 4A11Homo sapiens (human)
aromatase activityCytochrome P450 4A11Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 4A11Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 4A11Homo sapiens (human)
monooxygenase activityCytochrome P450 4F3Homo sapiens (human)
iron ion bindingCytochrome P450 4F3Homo sapiens (human)
heme bindingCytochrome P450 4F3Homo sapiens (human)
leukotriene-B4 20-monooxygenase activityCytochrome P450 4F3Homo sapiens (human)
aromatase activityCytochrome P450 4F3Homo sapiens (human)
20-hydroxy-leukotriene B4 omega oxidase activityCytochrome P450 4F3Homo sapiens (human)
20-aldehyde-leukotriene B4 20-monooxygenase activityCytochrome P450 4F3Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
monooxygenase activityCytochrome P450 2A13Homo sapiens (human)
iron ion bindingCytochrome P450 2A13Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A13Homo sapiens (human)
heme bindingCytochrome P450 2A13Homo sapiens (human)
aromatase activityCytochrome P450 2A13Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A13Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A13Homo sapiens (human)
arachidonic acid omega-hydroxylase activityCytochrome P450 4A22Homo sapiens (human)
iron ion bindingCytochrome P450 4A22Homo sapiens (human)
heme bindingCytochrome P450 4A22Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 4A22Homo sapiens (human)
16-hydroxypalmitate dehydrogenase activityCytochrome P450 4A22Homo sapiens (human)
medium-chain fatty acid omega-hydroxylase activityCytochrome P450 4A22Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 4A22Homo sapiens (human)
alkane 1-monooxygenase activityCytochrome P450 4A22Homo sapiens (human)
iron ion bindingVitamin D 25-hydroxylaseHomo sapiens (human)
heme bindingVitamin D 25-hydroxylaseHomo sapiens (human)
vitamin D3 25-hydroxylase activityVitamin D 25-hydroxylaseHomo sapiens (human)
protein homodimerization activityVitamin D 25-hydroxylaseHomo sapiens (human)
D3 vitamins bindingVitamin D 25-hydroxylaseHomo sapiens (human)
steroid hydroxylase activityVitamin D 25-hydroxylaseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenVitamin D 25-hydroxylaseHomo sapiens (human)
monooxygenase activityCytochrome P450 2U1Homo sapiens (human)
iron ion bindingCytochrome P450 2U1Homo sapiens (human)
arachidonic acid omega-hydroxylase activityCytochrome P450 2U1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 2U1Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2U1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2U1Homo sapiens (human)
heme bindingCytochrome P450 2U1Homo sapiens (human)
retinoic acid bindingCytochrome P450 2W1Homo sapiens (human)
monooxygenase activityCytochrome P450 2W1Homo sapiens (human)
all-trans retinal bindingCytochrome P450 2W1Homo sapiens (human)
iron ion bindingCytochrome P450 2W1Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2W1Homo sapiens (human)
all-trans-retinol bindingCytochrome P450 2W1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2W1Homo sapiens (human)
heme bindingCytochrome P450 2W1Homo sapiens (human)
G protein-coupled receptor activityTrace amine-associated receptor 1Homo sapiens (human)
trace-amine receptor activityTrace amine-associated receptor 1Homo sapiens (human)
monooxygenase activityCytochrome P450 2S1Homo sapiens (human)
thromboxane-A synthase activityCytochrome P450 2S1Homo sapiens (human)
iron ion bindingCytochrome P450 2S1Homo sapiens (human)
protein bindingCytochrome P450 2S1Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2S1Homo sapiens (human)
hydro-lyase activityCytochrome P450 2S1Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityCytochrome P450 2S1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 2S1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2S1Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2S1Homo sapiens (human)
heme bindingCytochrome P450 2S1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A43 Homo sapiens (human)
iron ion bindingCytochrome P450 3A43 Homo sapiens (human)
heme bindingCytochrome P450 3A43 Homo sapiens (human)
aromatase activityCytochrome P450 3A43 Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A43 Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A43 Homo sapiens (human)
protein bindingREST corepressor 3Homo sapiens (human)
transcription corepressor activityREST corepressor 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
chromatinLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
chromosome, telomeric regionLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
nucleoplasmLysine-specific histone demethylase 1AHomo sapiens (human)
transcription regulator complexLysine-specific histone demethylase 1AHomo sapiens (human)
protein-containing complexLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair complexLysine-specific histone demethylase 1AHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
mitochondrial inner membraneCytochrome P450 2E1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2E1Homo sapiens (human)
cytoplasmCytochrome P450 2E1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2E1Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4B1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneCytochrome P450 2B6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2B6Homo sapiens (human)
cytoplasmCytochrome P450 2B6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A5Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A5Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A7Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A7Homo sapiens (human)
cytoplasmCytochrome P450 2A7Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A7Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2F1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2F1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2F1Homo sapiens (human)
cytoplasmCytochrome P450 2F1Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C18Homo sapiens (human)
plasma membraneCytochrome P450 2C18Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C18Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C18Homo sapiens (human)
cytoplasmCytochrome P450 2C18Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytoplasmCytochrome P450 4F2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4F2Homo sapiens (human)
apical plasma membraneCytochrome P450 4F2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 4F2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4F8Homo sapiens (human)
cytoplasmCytochrome P450 4A11Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4A11Homo sapiens (human)
apical plasma membraneCytochrome P450 4A11Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 4A11Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 4A11Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4F3Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A13Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A13Homo sapiens (human)
cytoplasmCytochrome P450 2A13Homo sapiens (human)
extracellular spaceCytochrome P450 4A22Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 4A22Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 4A22Homo sapiens (human)
endoplasmic reticulum membraneVitamin D 25-hydroxylaseHomo sapiens (human)
intracellular membrane-bounded organelleVitamin D 25-hydroxylaseHomo sapiens (human)
cytoplasmVitamin D 25-hydroxylaseHomo sapiens (human)
mitochondrial inner membraneCytochrome P450 2U1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2U1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2U1Homo sapiens (human)
cytoplasmCytochrome P450 2U1Homo sapiens (human)
endoplasmic reticulum lumenCytochrome P450 2W1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2W1Homo sapiens (human)
plasma membraneCytochrome P450 2W1Homo sapiens (human)
cell surfaceCytochrome P450 2W1Homo sapiens (human)
cytoplasmCytochrome P450 2W1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2W1Homo sapiens (human)
plasma membraneTrace amine-associated receptor 1Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2S1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2S1Homo sapiens (human)
cytoplasmCytochrome P450 2S1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2S1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A43 Homo sapiens (human)
nucleoplasmREST corepressor 3Homo sapiens (human)
cytosolREST corepressor 3Homo sapiens (human)
histone deacetylase complexREST corepressor 3Homo sapiens (human)
transcription regulator complexREST corepressor 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (121)

Assay IDTitleYearJournalArticle
AID1773387Antiproliferative activity against human EC109 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID1863228Inhibition of CYP2C19 in human liver microsomes using S-mephenytoin as substrate and measured by LC-MS/MS analysis2022European journal of medicinal chemistry, Oct-05, Volume: 2404th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors.
AID1773372Inhibition of recombinant full length LSD1 (unknown origin) transfected in Escherichia coli BL21 (DE) using H3K4me2 as substrate by flourescence based analysis
AID639769Ratio of Kinact to Ki for MAO B2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Lysine demethylases inhibitors.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1575526Inhibition of MAOB (unknown origin) using luminogenic substrate incubated for 1 hr by luminescence based assay2019MedChemComm, May-01, Volume: 10, Issue:5
Dual inhibitors of LSD1 and spermine oxidase.
AID366633Lipophilicity, log D at pH 7.42008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases A and B by 2-aryl-2-fluoro-cyclopropylamines.
AID1368695Inhibition of human recombinant LSD1 incubated for 30 mins using H3K4me2 peptide substrate by fluorescence assay2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
AID604030Growth inhibition of human HEK293 cells after 48 hrs by MTT assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID341211Agonist activity at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization by calcium 3 assay relative to 2-phenylethanamine2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity correlations for beta-phenethylamines at human trace amine receptor 1.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1389957Inhibition of HDAC in human MCF7 cell nuclear extract using acetylated lysine as substrate at 1000 uM after 1 hr in presence of vorinostat by colorimetric analysis relative to control2018Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6
Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
AID1737492Selectivity ratio of relative binding affinity for human ERalpha LBD to relative binding affinity for human ERbeta LBD2020European journal of medicinal chemistry, Jun-01, Volume: 195Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1575529Inhibition of PAOX (unknown origin) assessed as decrease in spermidine formation using N-acetylspermine as substrate at 10 uM treated with compound 2 mins prior to substrate addition followed by further incubation for 1 hr by HPLC analysis relative to con2019MedChemComm, May-01, Volume: 10, Issue:5
Dual inhibitors of LSD1 and spermine oxidase.
AID366632Dissociation constant, pKa by titrimetric method2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases A and B by 2-aryl-2-fluoro-cyclopropylamines.
AID1773389Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID1737493Inhibition of LSD1 (unknown origin) at 10 uM incubated for 90 mins by fluorescence based assay relative to control2020European journal of medicinal chemistry, Jun-01, Volume: 195Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
AID1737495Inhibition of LSD1 (unknown origin) incubated for 90 mins by fluorescence based assay2020European journal of medicinal chemistry, Jun-01, Volume: 195Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
AID604027Inhibition of partially purified LSD1 using histone H3K4Me2 peptide substrate by peroxidase-coupled assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor.
AID1702776Cytotoxicity against human MGC-803 cells assessed as reduction in cell viability after 48 hrs by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187[1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
AID1702767Inhibition of recombinant human LSD1 (157 to 852 residues) expressed in Escherichia coli BL21 (DE) cells using H3K4me2 substrate incubated for 30 mins by amplex red assay2020European journal of medicinal chemistry, Feb-01, Volume: 187[1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
AID328945Ratio of Kinact to KI of human MAOA2008Bioorganic & medicinal chemistry letters, May-15, Volume: 18, Issue:10
Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.
AID1389219Inhibition of GST-fused human recombinant LSD1 demethylase activity expressed in Escherichia coli BL21 at 50 uM using H3K4me2 as substrate after 1 hr by mass-spectrometric analysis2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
AID353103Displacement of [3H]MK801 from NMDA receptor in rat brain neuronal membrane2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds.
AID1681676Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane incubated for 120 mins by solid scintillation counting method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Fluorinated 2-Arylcyclopropan-1-amines - A new class of sigma receptor ligands.
AID1755566Inhibition of N-terminal 6histidine-tagged LSD1 (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Peroxide production using 4[ARTK(diMe)QTARKSTGGKAPRKQLA] as substrate by 4-AAP/3,5-DCHBS and amplex red dye based HRP-c2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
AID1575521Inhibition of recombinant LSD1/CoREST (unknown origin) at 10 uM incubated for 30 mins to 4 hrs by fluorescence based assay relative to control2019MedChemComm, May-01, Volume: 10, Issue:5
Dual inhibitors of LSD1 and spermine oxidase.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID639767Ratio of Kinact to Ki for MAO A2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Lysine demethylases inhibitors.
AID1572510Inhibition of full length human menin/FAM-tagged MLL1 (unknown origin) protein-protein interaction after 15 mins by fluorescence polarization assay2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.
AID1368701Inhibition of human recombinant LSD1 at 100 uM incubated for 30 mins using H3K4me2 peptide substrate by fluorescence assay2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
AID1702777Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 48 hrs by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187[1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
AID604031Growth inhibition of human SH-SY5Y cells after 48 hrs by MTT assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor.
AID1368697Inhibition of human MAOB using (4S)-4, 5-dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazolecarboxylic acid substrate incubated for 60 mins by MAO-Glo assay2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
AID1282330Inhibition of full length N-terminal His-tagged human recombinant LSD1 (1 to 852 residues) expressed in Escherichia coli BL21(DE3) cells using H3K4me2 peptide as substrate preincubated for 5 mins followed by substrate addition measured for 30 mins by pero2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
AID1773381Reversible inhibition of recombinant full length LSD1 (unknown origin) transfected in Escherichia coli BL21 (DE) assessed as enzyme recovery activity by jump dilution assay relative to control
AID1737494Inhibition of LSD1 (unknown origin) at 50 uM incubated for 90 mins by fluorescence based assay relative to control2020European journal of medicinal chemistry, Jun-01, Volume: 195Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
AID353104Ratio of Ki for rat brain NMDA receptor in presence of 100 uM spermine to Ki for rat brain NMDA receptor in absence of spermine2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds.
AID1773388Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID1536074Selectivity ratio of IC50 for recombinant human MAOB expressed in baculovirus infected BTI insect cells to IC50 for human N-terminal GST-tagged LSD1 isoform2 (158 to end residues) expressed in Escherichia coli2019Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4
Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
AID1773384Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID1388930Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using (4S)-4,5-dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazolecarboxylic acid as substrate measured after 60 mins by chemiluminescence assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
AID1389950Cytotoxic activity against human MCF7 cells after 24 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6
Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
AID1813644Inhibition of CYP2C19 in human liver microsome using mephenytoin as substrate2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1389949Inhibition of human recombinant LSD1/CoREST3 expressed in Escherichia coli using monomethylatedH3meK4 peptide as substrate preincubated for 15 mins followed by substrate addition measured after 12 mins by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6
Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
AID341210Agonist activity at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization by calcium 3 assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity correlations for beta-phenethylamines at human trace amine receptor 1.
AID1681677Displacement of [3H]-di-o-tolylguanidine from Sigma 2 receptor in rat liver membrane incubated for 120 mins by solid scintillation counting method2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Fluorinated 2-Arylcyclopropan-1-amines - A new class of sigma receptor ligands.
AID1389236Growth inhibition of human HCT116 cells after 16 hrs by microscopic analysis2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
AID603121Inhibition of human recombinant His-tagged full length LSD1 expressed in Escherichia coli BL21 (DE3) assessed as inactivation constant preincubated for 20 mins with substrate measured after 30 mins by AmplexRed based fluorescence quenching assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.
AID603123Growth inhibition of human LNCAP cells after 6 days2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.
AID1388928Growth inhibition of human A549 cells after 72 hrs by Alamarblue assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
AID1282333Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI insect cells using (4S)-4,5-dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazolecarboxylic acid as substrate incubated for 60 mins by MAO-Glo assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
AID1572509Inhibition of recombinant human LSD1 (172 to 852 residues) using biotin-labelled H3K4me2 (1 to 24 residues) after 1 hr by TR-FRET assay2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.
AID639766Inhibition of MAO A2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Lysine demethylases inhibitors.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID328943Inhibition of human MAOB2008Bioorganic & medicinal chemistry letters, May-15, Volume: 18, Issue:10
Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.
AID1617368Inhibition of human CYP2C19 by fluorescence method2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Development of Robust 17(
AID1389218Inhibition of GST-fused human recombinant LSD1 demethylase activity expressed in Escherichia coli BL21 at 500 uM using H3K4me2 as substrate after 1 hr by mass-spectrometric analysis2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
AID1274608Inhibition of rat MAO-B using benzylamine as substrate2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.
AID1755622Inhibition of human MAO-B expressed in baculovirus infected BTI insect cells using tyramine as substrate by 4-AAP/3,5-DCHBS and amplex red dye based HRP-coupled assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
AID328944Ratio of Kinact to KI of human LSD12008Bioorganic & medicinal chemistry letters, May-15, Volume: 18, Issue:10
Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.
AID1389960Inhibition of HDAC1/CoREST3 in HEK293 whole cell extract using fluorescent acetylated histone peptide as substrate after 60 mins by fluorescence based assay2018Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6
Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
AID1536072Inhibition of recombinant human MAOB expressed in baculovirus infected BTI insect cells using beetle luciferin as substrate after 1 hr by MAO-Glo assay2019Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4
Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
AID1572512Inhibition of MAOB (unknown origin) by Promega MAO-Glo assay2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.
AID1737490Binding affinity to purified human ERalpha LBD incubated for 2 hrs by fluorescence tracer based competitive fluorometric binding assay relative to 17beta-estradiol2020European journal of medicinal chemistry, Jun-01, Volume: 195Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
AID1737496Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay2020European journal of medicinal chemistry, Jun-01, Volume: 195Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
AID1536071Inhibition of recombinant human MAOA expressed in baculovirus infected BTI insect cells using beetle luciferin as substrate after 1 hr by MAO-Glo assay2019Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4
Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
AID328942Inhibition of human MAOA2008Bioorganic & medicinal chemistry letters, May-15, Volume: 18, Issue:10
Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.
AID1773382Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID639768Inhibition of MAO B2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Lysine demethylases inhibitors.
AID1575524Inhibition of MAOA (unknown origin) using luminogenic substrate incubated for 1 hr by luminescence based assay2019MedChemComm, May-01, Volume: 10, Issue:5
Dual inhibitors of LSD1 and spermine oxidase.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1755621Inhibition of human MAO-A expressed in baculovirus infected BTI insect cells using tyramine as substrate by 4-AAP/3,5-DCHBS and amplex red dye based HRP-coupled assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
AID1575527Inhibition of SMOX (unknown origin) assessed as decrease in spermidine formation using spermine as substrate at 10 uM treated with compound 2 mins prior to substrate addition followed by further incubation for 1 hr by HPLC analysis relative to control2019MedChemComm, May-01, Volume: 10, Issue:5
Dual inhibitors of LSD1 and spermine oxidase.
AID1536073Selectivity ratio of IC50 for recombinant human MAOA expressed in baculovirus infected BTI insect cells to IC50 for human N-terminal GST-tagged LSD1 isoform2 (158 to end residues) expressed in Escherichia coli2019Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4
Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
AID1773385Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID1389239Growth inhibition of mouse NIH/3T3 cells after 16 hrs by microscopic analysis2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
AID1536068Inhibition of human N-terminal GST-tagged LSD1 isoform2 (158 to end residues) expressed in Escherichia coli using methylated peptide as substrate preincubated with substrate for 15 mins followed by enzyme addition and measured after 30 mins by amplex red 2019Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4
Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
AID639765Ratio of Kinact to Ki for LSD12011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Lysine demethylases inhibitors.
AID1274609Inhibition of LSD1 (unknown origin)2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.
AID604029Growth inhibition of human HeLa cells after 48 hrs by MTT assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor.
AID1282332Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells using (4S)-4,5-dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazolecarboxylic acid as substrate incubated for 60 mins by MAO-Glo assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
AID366635Inhibition of human recombinant MAOB2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases A and B by 2-aryl-2-fluoro-cyclopropylamines.
AID1721036Inhibition of CYP2C19 in human liver microsomes after 20 mins by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis.
AID1669136Inhibition of recombinant N-terminal His-tagged LSD1 (unknown origin) expressed in Escherichia coli expression system using ART-K(Me1)-QTARKSTGGKAPRKQLAGGK(Biotin) as substrate incubated for 60 mins by TR-FRET assay2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors.
AID1854419Binding affinity to LSD1 (unknown origin) assessed as inhibition constant2022European journal of medicinal chemistry, Oct-05, Volume: 240A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors.
AID1614067Inhibition of recombinant human CYP2B62019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Evaluation of Amides, Carbamates, Sulfonamides, and Ureas of 4-Prop-2-ynylidenecycloalkylamine as Potent, Selective, and Bioavailable Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5.
AID1382512Inhibition of MAO-B (unknown origin) by luminescence assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Cyclic peptide inhibitors of lysine-specific demethylase 1 with improved potency identified by alanine scanning mutagenesis.
AID318314Inhibition of human CYP2C192008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent disease
AID328946Ratio of Kinact to KI of human MAOB2008Bioorganic & medicinal chemistry letters, May-15, Volume: 18, Issue:10
Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.
AID1702765Cytotoxicity against human EC-109 cells assessed as reduction in cell viability after 48 hrs by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187[1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
AID1773391Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID1702778Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability after 48 hrs by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187[1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
AID1515260Inhibition of LSD1 (unknown origin) by fluorescence assay2019Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2
Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.
AID1572511Inhibition of MAOA (unknown origin) by Promega MAO-Glo assay2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.
AID1739439Inhibition of CYP2C19 in human liver microsomes using omeprazole as substrate incubated for 5 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID1388929Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using (4S)-4,5-dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazolecarboxylic acid as substrate measured after 60 mins by chemiluminescence assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
AID1389238Growth inhibition of mouse F9 cells after 16 hrs by microscopic analysis2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
AID1773383Antiproliferative activity against human NCI-H1650 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID639764Inhibition of LSD12011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Lysine demethylases inhibitors.
AID1389237Growth inhibition of human PA1 cells after 16 hrs by microscopic analysis2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
AID1388927Inhibition of recombinant human LSD1 using H3K4me2 peptide as substrate measured after 30 mins by fluorescence assay2018Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3
Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
AID1389955Cytotoxic activity against human MCF7 cells at > 70 uM after 24 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6
Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
AID1368696Inhibition of human MAOA using (4S)-4, 5-dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazolecarboxylic acid substrate incubated for 60 mins by MAO-Glo assay2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
AID1572513Antiproliferative activity against human MV4-11 cells after 168 hrs by MTS assay2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.
AID318312Inhibition of human CYP2B62008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent disease
AID366636Selectivity for human recombinant MAOB over human recombinant MAOA2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases A and B by 2-aryl-2-fluoro-cyclopropylamines.
AID1614065Inhibition of recombinant human CYP2C192019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Evaluation of Amides, Carbamates, Sulfonamides, and Ureas of 4-Prop-2-ynylidenecycloalkylamine as Potent, Selective, and Bioavailable Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5.
AID1737491Binding affinity to purified human ERbeta LBD incubated for 2 hrs by fluorescence tracer based competitive fluorometric binding assay relative to 17beta-estradiol2020European journal of medicinal chemistry, Jun-01, Volume: 195Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
AID603122Inhibition of human truncated LSD1 lacking N-terminal 184 amino acids2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.
AID1274607Inhibition of rat MAO-A using serotonin as substrate incubated for 1 hr2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.
AID1773390Antiproliferative activity against human BGC-823 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID1382511Inhibition of MAO-A (unknown origin) by luminescence assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Cyclic peptide inhibitors of lysine-specific demethylase 1 with improved potency identified by alanine scanning mutagenesis.
AID328941Inhibition of human LSD12008Bioorganic & medicinal chemistry letters, May-15, Volume: 18, Issue:10
Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.
AID1756367Inhibition of CYP2C19 in human liver microsomes using Mephenytoin as substrate measured after 20 mins by LC-MS/MS analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.
AID1773386Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID366634Inhibition of human recombinant MAOA2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases A and B by 2-aryl-2-fluoro-cyclopropylamines.
AID1617365Inhibition of human CYP2B6 by fluorescence method2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Development of Robust 17(
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,736)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901202 (69.24)18.7374
1990's203 (11.69)18.2507
2000's134 (7.72)29.6817
2010's154 (8.87)24.3611
2020's43 (2.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.99 (24.57)
Research Supply Index7.56 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index110.77 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials94 (5.15%)5.53%
Reviews70 (3.83%)6.00%
Case Studies196 (10.73%)4.05%
Observational0 (0.00%)0.25%
Other1,466 (80.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (29)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty [NCT03328832]Phase 470 participants (Actual)Interventional2017-09-12Completed
Blood-saving Effect of Combined Intravenous Tranexamic Acid With Topical Floseal® Application, a Comparison With Intravenous Tranexamic Acid Only in Total Hip Arthroplasty [NCT03623789]Phase 490 participants (Anticipated)Interventional2018-08-15Recruiting
Phase I/II Pilot Trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) and no Intensive Treatment is Possible [NCT02261779]Phase 1/Phase 216 participants (Anticipated)Interventional2014-09-30Recruiting
Tranexamic Acid Reduces Blood Loss in Pediatric Cardiac Surgery [NCT00994994]160 participants (Actual)Interventional2006-01-31Completed
To Compare Bioavailability of Kali Tranylcypromine 10mg Tablets to That of Parnate 10 mg Tablets Under Fasting Conditions. [NCT00653393]Phase 139 participants (Actual)Interventional2004-10-31Completed
Phase I/II Study of Sensitization of Non-M3 Acute Myeloid Leukemia (AML) Blasts to All-trans Retinoic Acid (ATRA) by Epigenetic Treatment With Tranylcypromine (TCP), an Inhibitor of the Histone Lysine Demethylase 1 (LSD1) [NCT02717884]Phase 1/Phase 260 participants (Anticipated)Interventional2015-05-31Recruiting
Comparison of Topical Tranexamic Acid and Floseal® on Blood Loss After Total Knee Arthroplasty in Patients With a Thromboembolic Risk [NCT02865174]Phase 490 participants (Anticipated)Interventional2016-09-30Not yet recruiting
Comparison of the Efficacy of Irrigation With Epinephrine or Tranexamic Acid on Visual Clarity During Arthroscopic Rotator Cuff Repair: A Randomized Double-Blind Study [NCT04628676]100 participants (Actual)Interventional2017-02-01Completed
Adapting Marital Therapy in Older Adults With Depression [NCT00612807]Phase 1/Phase 242 participants (Actual)Interventional2006-07-31Completed
Evaluation and Treatment of Autonomic Failure. [NCT00223691]Phase 1389 participants (Actual)Interventional2002-03-31Completed
Reduction Perioperative Bleeding in Laminectomy With Instrumentation or More Than or Equal to 3 Levels Laminectomy: The Comparison Between Placebo, and Double Doses of Tranexamic Acid (15 mg/kg and 15 mg/kg) [NCT01643135]Phase 478 participants (Actual)Interventional2012-06-30Completed
A Phase 1 Dose Escalation Study of Tranylcypromine (TCP) in Combination With ATRA (Tretinoin) for Adult Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) [NCT02273102]Phase 117 participants (Actual)Interventional2015-03-02Completed
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study [NCT00177567]Phase 460 participants Interventional2001-07-31Completed
A Pilot Study of Treatment for Refractory Depression With Sequential Trials of Tranylcypromine, Tranylcypromine Plus Dextroamphetamine, Tranylcypromine Plus Triiodothyronine. [NCT00296686]Phase 431 participants (Actual)Interventional2001-09-30Terminated(stopped due to Study is no longer funded.)
Comparative Study Between Chemical Peeling With 70% Glycolic Acid and Intradermal Transamine for the Treatment of Melasma. [NCT05362500]Phase 154 participants (Actual)Interventional2021-06-01Completed
The Comparison of the Effectiveness of Rectal Misoprostol and Intravenous Tranexamic Acid in Reducing Intraoperative Bleeding in Patients Undergoing Myomectomy [NCT06114758]75 participants (Actual)Observational [Patient Registry]2023-09-01Active, not recruiting
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) [NCT00012558]5,000 participants Interventional1998-09-30Completed
Sequenced Treatment Alternatives to Relieve Depression [NCT00021528]Phase 44,000 participants Interventional2001-07-31Completed
Early Administration of Intravenous Tranexamic Acid for Upper Gastrointestinal Bleeding Prior to Endoscopy [NCT01713101]Phase 3414 participants (Anticipated)Interventional2012-10-31Recruiting
The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis [NCT02458729]Phase 4294 participants (Actual)Interventional2012-08-31Completed
Randomized, Double-blind, Placebo-controlled Trial to Investigate the Effectiveness of Early Intravenous Tranexamic Acid in Limiting Hematoma Expansion in Patients With Spontaneous Intracerebral Hemorrhage [NCT03044184]Phase 3220 participants (Anticipated)Interventional2017-04-01Recruiting
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression [NCT01896349]74 participants (Anticipated)Interventional2013-04-30Recruiting
Use of Tranexamic Acid in Postoperative Early Period Bleeding in Patients Undergoing Sleeve Gastrectomy: A Randomized Controlled Trial [NCT05696951]200 participants (Actual)Interventional2022-01-01Completed
Blood-saving Effect of Kaolin-based Hemostatic Gauze Combined With Intravenous Tranexamic Acid in Total Knee Arthroplasty [NCT05504577]Phase 4120 participants (Anticipated)Interventional2022-03-16Recruiting
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial. [NCT05737511]Phase 480 participants (Anticipated)Interventional2023-12-30Not yet recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
Tranylcypromine Treatment of Bipolar Depression [NCT01430455]Phase 47 participants (Actual)Interventional2011-11-30Completed
Developing a Biomarker to Predict Response in Treatment Resistant Depression [NCT01031810]Phase 413 participants (Actual)Interventional2009-11-30Terminated(stopped due to Needed PET facility closed)
Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty [NCT02453802]Phase 490 participants (Anticipated)Interventional2015-06-30Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00612807 (2) [back to overview]Dyadic Adjustment Scale (DAS)
NCT00612807 (2) [back to overview]Hamilton Depression Rating Scale (HDRS)
NCT01031810 (6) [back to overview]Hamilton Depression Rating Scale Scores 17 at Baseline
NCT01031810 (6) [back to overview]Hamilton Depression Rating Scale Scores 17 at week12
NCT01031810 (6) [back to overview]Quick Inventory of Depression- Self Report 16
NCT01031810 (6) [back to overview]Quick Inventory of Depression- Self Report 16
NCT01031810 (6) [back to overview]Quick Inventory of Depression- Self Report 16
NCT01031810 (6) [back to overview]Quick Inventory of Depression- Self Report 16
NCT01430455 (1) [back to overview]29 Item Hamilton Rating Scale for Depression (HamD29)
NCT03328832 (3) [back to overview]Blood Transfusion Rate
NCT03328832 (3) [back to overview]Incidence of Thrombosis Events
NCT03328832 (3) [back to overview]Total Blood Loss After Operation

Dyadic Adjustment Scale (DAS)

The DAS is a self-report measure of marital adjustment that includes questions about agreement on lifestyle and household decisions, level of conflict, level of cooperation, and affection. Scores range from 0 to 151, with higher scores representing better relationship functioning. (NCT00612807)
Timeframe: pre-treatment, monthly, post-treatment, 6 month follow-up

,
InterventionScore on DAS measure (Mean)
Baseline assessment (Depressed spouse)Post-test assessment (Depressed spouse)Follow-up assessment (Depressed spouse)Baseline assessment (Non-depressed spouse)Post-test assessment (Non-depressed spouse)Follow-up assessment (Non-depressed spouse)
Semi-weekly Medication Management72.1484.1789.6791.093.33104.17
Semi-weekly Medication Management + Weekly Marital Therapy84.4392.2791.0788.2997.5798.31

[back to top]

Hamilton Depression Rating Scale (HDRS)

The HDRS is a semi-structured interview administered by a trained independent evaluator, and used for rating the severity of depressive symptoms. Scores range from 0 to 50, with higher scores indicating greater severity of depression. (NCT00612807)
Timeframe: pre-treatment, monthly, post-treatment, 6 month follow-up

,
InterventionScore on HDRS (Mean)
Baseline assessment (Depressed spouse)Post-test assessment (Depressed spouse)Follow-up assessment (Depressed spouse)Baseline assessment (Non-depressed spouse)Post-test assessment (Non-depressed spouse)Follow-up assessment (Non-depressed spouse)
Semi-weekly Medication Management17.865.009.175.145.333.83
Semi-weekly Medication Management + Weekly Marital Therapy19.07.298.148.863.295.71

[back to top]

Hamilton Depression Rating Scale Scores 17 at Baseline

"HAM-D is a multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. Each item on the questionnaire is scored on a 3 or 5 point scale, depending on the item, and the total score is compared to the corresponding descriptor.~Scale range (0-52):~A score of 0-7 is considered to be normal. Scores of 20 or higher indicate moderate, severe, or very severe depression, and are usually required for entry into a clinical trial." (NCT01031810)
Timeframe: Week 00 (baseline)

Interventionunits on a scale (Mean)
Tranylcypromine23.2

[back to top]

Hamilton Depression Rating Scale Scores 17 at week12

"HAM-D is a multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. Each item on the questionnaire is scored on a 3 or 5 point scale, depending on the item, and the total score is compared to the corresponding descriptor.~Scale range (0-52):~A score of 0-7 is considered to be normal. Scores of 20 or higher indicate moderate, severe, or very severe depression, and are usually required for entry into a clinical trial." (NCT01031810)
Timeframe: Week 12

InterventionScore on a scale (Mean)
Tranylcypromine11.67

[back to top]

Quick Inventory of Depression- Self Report 16

"Quick Inventory of Depression- Self Report assesses 16 depressive symptoms experienced in the past week, based on self-rating, measured at study exit visit~Scale range (0-27):~Each of the four possible answers to each quiz is given an ascending numerical value from 0 to 3, and the total test score is the sum of the following: The highest number from questions 1-4 The number from question 5 The highest number from questions 6-9 The total of each question from 10-14 The highest number from questions 15-16~Total score interpretation: 0-5 no depression, 6-10 mild depression, 11-15 moderate depression, 16-20 severe depression, 20 and above very severe depression" (NCT01031810)
Timeframe: Week 04

Interventionunits on a scale (Mean)
Tranylcypromine13.0

[back to top]

Quick Inventory of Depression- Self Report 16

"Quick Inventory of Depression- Self Report assesses 16 depressive symptoms experienced in the past week, based on self-rating, measured at study exit visit~Scale range (0-27):~Each of the four possible answers to each quiz is given an ascending numerical value from 0 to 3, and the total test score is the sum of the following: The highest number from questions 1-4 The number from question 5 The highest number from questions 6-9 The total of each question from 10-14 The highest number from questions 15-16~Total score interpretation: 0-5 no depression, 6-10 mild depression, 11-15 moderate depression, 16-20 severe depression, 20 and above very severe depression" (NCT01031810)
Timeframe: Week 12

Interventionunits on a scale (Mean)
Tranylcypromine10.38

[back to top]

Quick Inventory of Depression- Self Report 16

"Quick Inventory of Depression- Self Report assesses 16 depressive symptoms experienced in the past week, based on self-rating, measured at study exit visit~Scale range (0-27):~Each of the four possible answers to each quiz is given an ascending numerical value from 0 to 3, and the total test score is the sum of the following: The highest number from questions 1-4 The number from question 5 The highest number from questions 6-9 The total of each question from 10-14 The highest number from questions 15-16~Total score interpretation: 0-5 no depression, 6-10 mild depression, 11-15 moderate depression, 16-20 severe depression, 20 and above very severe depression" (NCT01031810)
Timeframe: Week 16

Interventionunits on a scale (Mean)
Tranylcypromine9.89

[back to top]

Quick Inventory of Depression- Self Report 16

"Quick Inventory of Depression- Self Report assesses 16 depressive symptoms experienced in the past week, based on self-rating, measured at study exit visit~Scale range (0-27):~Each of the four possible answers to each quiz is given an ascending numerical value from 0 to 3, and the total test score is the sum of the following: The highest number from questions 1-4 The number from question 5 The highest number from questions 6-9 The total of each question from 10-14 The highest number from questions 15-16~Total score interpretation: 0-5 no depression, 6-10 mild depression, 11-15 moderate depression, 16-20 severe depression, 20 and above very severe depression" (NCT01031810)
Timeframe: Weeks 00

Interventionunits on a scale (Mean)
Tranylcypromine17.78

[back to top]

29 Item Hamilton Rating Scale for Depression (HamD29)

29 Item Hamilton Rating Scale for Depression (HamD29) is the 29 item version of the most common depression rating scale. The scores represented here are the average scores at baseline and after 16 weeks of open label treatment. The scale is rated from 0-89 with higher scores representing a more depressed state. (NCT01430455)
Timeframe: Hamilton 29 score at baseline (start date of medication) and week 16

InterventionHamilton Depression score (Mean)
Baseline ScoreWeek 16 Score
Tranylcypromine27.05.8

[back to top]

Blood Transfusion Rate

We will record the event of blood transfusion, and calculate the incidence of transfusion (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4

InterventionParticipants (Count of Participants)
Combined Topical TXA and Floseal1
Topical TXA Alone0

[back to top]

Incidence of Thrombosis Events

The composite of any venous thromoembolism events, ischemic heart attacks, cerebrovascular accidents (NCT03328832)
Timeframe: within 30 days of the operation

InterventionParticipants (Count of Participants)
Combined Topical TXA and Floseal0
Topical TXA Alone0

[back to top]

Total Blood Loss After Operation

Total blood loss was calculated according to Nadler et al., which used maximum postoperative reduction of the Hb level adjust for weight and height of the patient. The formula is as follows, Total blood loss = (Total blood volume x [change in Hb level / preoperative Hb level])x1000+volume transfused (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4

Interventionml (Mean)
Combined Topical TXA and Floseal678
Topical TXA Alone733

[back to top]